Trump Advances Psychedelic Treatments

President Trump’s Landmark Order Advances Breakthrough Mental Health Treatments — Delivering New Hope to Veterans

The Big Picture: Key Points

• President Donald J. Trump signed an Executive Order to accelerate research and improve access to psychedelic drugs as treatments for serious mental illnesses.
• The order prioritizes breakthroughs that could offer new hope to millions of Americans, particularly veterans, who face high rates of suicide and often don’t respond to conventional therapies.
• Veterans’ organizations, medical professionals, patient advocates, and industry leaders welcomed the historic action, citing the potential of psychedelic medicines to address the mental health crisis in America.

The recent Executive Order signed by President Donald J. Trump marks a significant shift in the approach to mental health treatments, especially for veterans. By accelerating research and improving access to psychedelic drugs, the order aims to provide new hope to millions of Americans struggling with serious mental illnesses. The move is particularly noteworthy for veterans, who have disproportionately high rates of suicide and often do not respond well to conventional therapies.

The order's focus on breakthroughs in psychedelic medicine is seen as a critical step towards addressing the mental health crisis in America. Veterans’ organizations, medical professionals, patient advocates, and industry leaders have all welcomed the historic action, recognizing the potential of psychedelic medicines to offer relief and healing to those who have been struggling with limited treatment options.

At the heart of this initiative is the recognition that conventional therapies have not been sufficient for many veterans. The high rates of suicide among this group underscore the urgent need for innovative and effective treatments. By prioritizing research into psychedelic drugs, the Executive Order signals a commitment to exploring all avenues that could lead to improved mental health outcomes for veterans and other Americans.

Reactions from Veterans’ Organizations and Medical Professionals

The response from veterans’ organizations and medical professionals has been overwhelmingly positive. W. Bryan Hubbard, CEO of Americans for Ibogaine, noted,

"This began with a small group who refused to accept the status quo and fought to bring ibogaine into the United States healthcare system, growing into a national movement that could not be ignored. We have always believed this was the moonshot of our time. People from every corner of this country came together and demanded better. Today, that movement has compelled action at the highest levels of the federal government. The era of federal prohibition of psychedelic medicine in America is coming to an end."

Americans for Ibogaine Chairman and Former Texas Gov. Rick Perry also commented,

"This is a historic moment for our Veterans and for this country. I have seen firsthand the impact ibogaine can have on our warfighters. For too long, they have been forced to leave the United States to access care. That should never have been the case. Today is a major step toward correcting that."

Support from the American Legion and Disabled American Veterans

The American Legion and Disabled American Veterans have also expressed their support for the Executive Order. American Legion National Commander Dan K. Wiley stated,

"Thanks to the advancements of research, there is hope that these psychedelic drugs will serve as a pathway to and promise of a brighter future for our veterans and their loved ones. We must ensure that any treatment brought forward is grounded in sound science, proven safe and accessible through the Department of Veterans Affairs when appropriate."

Disabled American Veterans National Commander Coleman Nee also applauded the president’s executive order,

"DAV applauds the president’s executive order to accelerate research and expand access to innovative plant-based therapies for veterans living with the invisible wounds of war. For far too many veterans, conditions like post-traumatic stress and traumatic brain injury remain inadequately treated by conventional approaches, leaving them without timely or effective care. This action represents a meaningful step toward closing that gap."

Industry Leaders’ Perspectives

Industry leaders have also welcomed the Executive Order. Association for Prescription Psychedelics Executive Director Jon Kostas thanked President Trump and other officials for their courage and sense of urgency,

"THANK YOU to President Trump, Secretary Kennedy, Administrator Oz, Commissioner Makary, and Secretary Collins for having the courage and sense of urgency to accelerate access to psychedelic medicines for those who need them most, particularly our veterans. Today’s Executive Order validates the critical unmet medical need to address the mental health crisis in America and the urgency for new and regulated, science-based innovations."

Beond Co-Founder and CEO Tom Feegel commended President Trump and Health and Human Services Secretary Robert F. Kennedy, Jr. for their visionary leadership,

"We commend President Donald J. Trump and Health and Human Services Secretary Robert F. Kennedy, Jr. for their visionary leadership in urgently advancing a forward-looking, science-driven approach to mental health. This Executive Order signals that psychedelics, in particular ibogaine, are now taken seriously at the highest levels of government not as a fringe concept, but as a component of the United States’ mission to lead the world in the development of the most advanced, outcomes-driven approach to mental health."

Funding Commitment and Regulatory Pathway

The Executive Order includes a $50 million Federal funding commitment to ibogaine research, expanded use of Right to Try pathways, expanded federal support for clinical research, and new funding mechanisms to support U.S. military veterans seeking access to ibogaine treatment in advanced, licensed, hospital-grade settings. Compass Pathways CEO Kabir Nath stated,

"Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science."

• The Executive Order includes a $50 million Federal funding commitment to ibogaine research.
• Expanded use of Right to Try pathways and expanded federal support for clinical research are part of the order.
• New funding mechanisms will support U.S. military veterans seeking access to ibogaine treatment in advanced settings.

FAQ

1. What is the main goal of President Trump’s Executive Order regarding psychedelic treatments? The main goal is to accelerate research and improve access to psychedelic drugs as treatments for serious mental illnesses, particularly for veterans.
2. Which organizations have welcomed the historic action? Veterans’ organizations, medical professionals, patient advocates, and industry leaders have welcomed the action, citing the potential of psychedelic medicines to address the mental health crisis in America.
3. What is the significance of the $50 million Federal funding commitment to ibogaine research? The funding commitment signals the government’s serious investment in exploring the therapeutic potential of psychedelics, particularly ibogaine, for treating mental health conditions in veterans and other Americans.
4. How does this Executive Order impact the future of mental health care for veterans? The order marks a significant shift towards innovative and effective treatments, offering new hope for improved mental health outcomes for veterans and other Americans struggling with serious mental illnesses.

For more information on the intersection of healthcare and policy, visit our Donald Trump topic page.